MiRNA-SARS-CoV-2 dialogue and prospective anti-COVID-19 therapies M Panda, E Kalita, S Singh, K Kumar, A Rao, VK Prajapati Life Sciences 305, 120761, 2022 | 32 | 2022 |
High-throughput virtual screening of small-molecule inhibitors targeting immune cell checkpoints to discover new immunotherapeutics for human diseases S Singh, K Kumar, M Panda, A Srivastava, A Mishra, VK Prajapati Molecular Diversity 27 (2), 729-751, 2023 | 17 | 2023 |
Translational vaccinomics and structural filtration algorithm to device multiepitope vaccine for catastrophic monkeypox virus S Singh, A Rao, K Kumar, A Mishra, VK Prajapati Computers in Biology and Medicine 153, 106497, 2023 | 11 | 2023 |
Nanobody-peptide-conjugate (NPC) for passive immunotherapy against SARS-CoV-2 variants of concern (VoC): a prospective pan-coronavirus therapeutics M Panda, E Kalita, S Singh, K Kumar, VK Prajapati Molecular Diversity 27 (6), 2577-2603, 2023 | 7 | 2023 |
Multi-pathogen based chimeric vaccine to fight against COVID-19 and concomitant coinfections R Ojha, S Singh, N Gupta, K Kumar, AK Padhi, VK Prajapati Biotechnology Letters 45 (7), 779-797, 2023 | 6 | 2023 |